Clostridium difficile infections and fidaxomicin treatment

Laura Fascio Pecetto

DOI: https://doi.org/10.7175/cmi.v8i1S.967

Full Text

HTML PDF

References

  • Goudarzi M, Seyedjavadi SS, Goudarzi H, et al. Clostridium difficile infection: epidemiology, pathogenesis, risk factors, and therapeutic options. Scientifica (Cairo) 2014; 2014: 916826; http://dx.doi.org/10.1155/2014/916826
  • Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. European Society of Clinical Microbiology and Infectious Diseases. Clin Microbiol Infect 2014; 20 Suppl 2: 1-26; http://dx.doi.org/10.1111/1469-0691.12418
  • EMA. Committee for Medicinal Products for Human Use (CHMP) EMA/223574/2014. Dificlir. Scientific conclusions and grounds recommending the variation to the terms of the marketing authorization, 2014. Disponibile all’indirizzo http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Conclusion/human/002087/WC500165688.pdf (ultimo accesso dicembre 2014)
  • Dificlir. Summary of product characteristics. Disponibile all’indirizzo http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002087/WC500119705.pdf (ultimo accesso dicembre 2014)

Statistics

Abstract: 628 views
HTML: 872 views
PDF: 469 views

Refbacks

  • There are currently no refbacks.




© SEEd srl